News ArticleBayer CropScience Declares Rs. 90 Interim Dividend and Reports Rs. 1,662 Million Profit for Q2 2026
Company announces unaudited Q2 and H1 FY 2026 financial results along with interim dividend payable November 30, 2026
Bayer CropScience Limited announced its unaudited financial results for the quarter and half year ended September 30, 2026, reporting a profit of Rs. 1,662 million for Q2 and Rs. 4,878 million for the six months. The company declared an interim dividend of Rs. 90 per equity share for financial year 2026-27, payable on November 30, 2026.
Bayer CropScience Limited
Financial Results
Bayer CropScience Limited announced an interim dividend of Rs. 90 per equity share for the financial year 2026-27 and reported a profit of Rs. 1,662 million for the quarter ended September 30, 2026. The company’s unaudited financial results for Q2 and the half year ended September 30, 2026, were approved by the Board of Directors.
The declared interim dividend will be paid on November 30, 2026, to shareholders registered as of the record date, November 12, 2026.
For Q2 ended September 30, 2026, Bayer CropScience recorded revenue from operations of Rs. 12,507 million and a profit before tax of Rs. 2,114 million, with net profit after tax amounting to Rs. 1,662 million.
For the six months ended September 30, 2026, total income reached Rs. 31,880 million with a reported profit after tax of Rs. 4,878 million.
The unaudited results comply with Indian Accounting Standards and were reviewed by the statutory auditor Deloitte Haskins & Sells LLP, who issued a limited review report with no qualifications.
The company's financial statements reflect a seasonal business and include one reportable segment: Agri Care.
Highlights
- Interim dividend declared at Rs. 90 per equity share of Rs. 10 each for FY 2026-27
- Q2 2026 profit after tax: Rs. 1,662 million
- Six months ended September 30, 2026 profit after tax: Rs. 4,878 million
- Revenue from operations for Q2 2026: Rs. 12,507 million
- Board meeting held on November 3, 2026; dividend payable on November 30, 2026
- Record date for dividend payment is November 12, 2026
Key Data Snapshot
What happened
- Bayer CropScience approved unaudited financial results for Q2 and half year ended September 30, 2026.
- The Board declared an interim dividend of Rs. 90 per equity share for FY 2026-27.
- Dividend payable on November 30, 2026, to shareholders recorded as of November 12, 2026.
Key details
- Revenue from operations for Q2 2026 was Rs. 12,507 million.
- Profit after tax for Q2 2026 stood at Rs. 1,662 million.
- For six months ended September 30, 2026, profit after tax totaled Rs. 4,878 million against total income of Rs. 31,880 million.
- Unaudited results reviewed without qualification by Deloitte Haskins & Sells LLP.
- Company operates in one reportable segment, Agri Care, with seasonal business effects influencing quarterly figures.
Regulatory and governance context
- Results were prepared as per Indian Accounting Standard 34 (Ind AS 34) and approved by the Board on November 3, 2026.
- The limited review report was issued by statutory auditors Deloitte Haskins & Sells LLP on the same date.
- Compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, 2015 observed.
Highlights
- Interim dividend declared at Rs. 90 per equity share of Rs. 10 each for FY 2026-27
- Q2 2026 profit after tax: Rs. 1,662 million
- Six months ended September 30, 2026 profit after tax: Rs. 4,878 million
- Revenue from operations for Q2 2026: Rs. 12,507 million
- Board meeting held on November 3, 2026; dividend payable on November 30, 2026
- Record date for dividend payment is November 12, 2026
Disclosures
- SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
- Indian Accounting Standard 34 (Ind AS 34)
- Companies Act, 2013
More News on Financial Results
View allLatest corporate announcements and market updates in Financial Results.
Biocon Limited Reports Rs. 1,439 Million Profit for H1 FY2026-27; Appoints Mukesh Rathi as New CTO from January 2027
Biocon Limited declared its unaudited standalone financial results for the quarter and half-year ended September 30, 2026, reporting a profit of Rs. 1,439 million for the half-year. Alongside financial disclosure, the company announced a change in its senior management with the resignation of CTO Dr. Mandar Shrikant Ghatnekar effective December 31, 2026, and the appointment of Mr. Mukesh Rathi as the new CTO starting January 1, 2027.
Read Full Story
Zydus Lifesciences Posts ₹10,541 Million Net Profit for Half Year Ending September 30, 2026
Zydus Lifesciences Limited announced its unaudited standalone financial results for the quarter and half year ended September 30, 2026, recording a net profit of ₹7,145 million for Q2 and ₹10,541 million for the half year.
Read Full Story
Fractal Analytics Limited Reports Unaudited Q2 and H1 2026 Financial Results and Approves Winding Up of Analytics Vidhya Inc
Fractal Analytics Limited announced its unaudited consolidated and standalone financial results for the quarter and half-year ended September 30, 2026. Additionally, the company's Board has approved winding up its step-down subsidiary Analytics Vidhya Inc., aiming to simplify group corporate structure and enhance operational efficiency without affecting ongoing business activities.
Read Full Story
